Clinical Trial Update: Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update investigating the effects of the SGLT2 inhibitor empagliflozin in patients with SIADH (SAND study).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Syndrome of Inappropriate Antidiuretic Hormone Secretion

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: SIADH | Phase 2, Phase 3 | Status: COMPLETED